Ignite Creation Date:
2024-05-05 @ 6:31 PM
Last Modification Date:
2024-10-26 @ 9:34 AM
Study NCT ID:
NCT00496470
Status:
COMPLETED
Last Update Posted:
2012-11-09
First Post:
2007-07-03
Brief Title:
Evaluation of Efficacy and Safety of Symbicort as an add-on Treatment to Spiriva in Patients With Severe COPD
Sponsor:
AstraZeneca
Organization:
AstraZeneca
Study Overview
Official Title:
A 12-week Double-blind Randomised Parallel Group Multi-centre Study to Evaluate Efficacy and Safety of BudesonideFormoterol Symbicort Turbuhaler 3209 µg One Inhalation Twice Daily on Top of Tiotropium Spiriva 18 µg One Inhalation Once Daily
Status:
COMPLETED
Status Verified Date:
2012-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to investigate the effect of combined treatment with Symbicort and Spiriva in terms of improvement of lung function symptoms and inflammatory markers in patients with severe COPD
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| Eudract no2006-006796-21 | None | None | None |